Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee, Zelos Zhu, Mark Jesus M. Magbanua, Rosalyn W. Sayaman, Nicholas O’Grady, Amrita Basu, Amy L. Delson, Jean Philippe Coppé, Ruixiao Lu, Jerome J. Braun, Smita Asare, Laura Sit, Jeffrey B. Matthews, Jane Perlmutter, Nola M. Hylton, Minetta C. Liu, Paula R. Pohlmann, W. Fraser Symmans, Hope S. Rugo, Claudine Isaacs, Angela DeMichele, Douglas Yee, Donald A. Berry, Lajos Pusztai, Emanuel F. Petricoin, Gillian L. Hirst, Laura J. Esserman, Laura van ‘t Veer
Abstract
subsets (>15%). As new treatments are introduced, the subtyping schema determines the minimum response needed to show efficacy. This data platform provides an unprecedented resource and supports the usage of response-based subtypes to guide future treatment prioritization.